hepatocellular carcinoma
FDA Approves SIR-Spheres for Unresectable HCC
The FDA approved yttrium-90 (Y-90) resin microspheres (SIR-Spheres, Sirtex Medical) for the treatment of ...
JULY 11, 2025
FDA Approves Opdivo With Yervoy for Unresectable or Metastatic Hepatocellular Carcinoma
The FDA has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for ...
APRIL 14, 2025
FDA Approves Opdivo Qvantig for Subcutaneous Injection
The FDA approved nivolumab plus hyaluronidase-nvhy (Opdivo Qvantig, Bristol Myers Squibb) for subcutaneous ...
DECEMBER 30, 2024
FDA Approves Tecentriq Hybreza for Subcutaneous Injection for All Adult Indications of IV Tecentriq
The FDA has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech) for subcutaneous injection ...
SEPTEMBER 16, 2024
First-Degree Relatives of MASLD Patients Are at Higher Risk for HCC
Some relatives of people with metabolic dysfunction–associated steatotic liver disease are at higher risk for ...
JANUARY 24, 2024
Without Effective MASLD Treatments, Cirrhosis, Cancer and Transplants Expected to Rise
Unless progress is made toward developing effective treatments for MASLD, the prevalence of the disease will ...
DECEMBER 25, 2023
Novel First-Line Therapy’s OS Benefit for Liver Cancer Persists
Long-term overall survival in hepatocellular carcinoma with tremelimumab plus durvalumab treatment is durable, ...
NOVEMBER 27, 2023
Tislelizumab Vies for First-Line Designation in Treatment of Advanced HCC
The checkpoint inhibitor tislelizumab might reasonably be considered a better choice for hepatocellular carcinoma ...
NOVEMBER 20, 2023
Albumin-Bilirubin Grade Proposed as Prognostic Tool in Hepatocellular Carcinoma
Results of a retrospective study suggest that the albumin-bilirubin grade might be more useful in classifying ...
NOVEMBER 11, 2023
Novel Use of Artificial Intelligence Shows Promise to Improve HCC Detection
An innovative use of artificial intelligence to find hepatocellular carcinoma could identify even small and ...
APRIL 17, 2023
Better Outcomes, No Reduced Safety When Sorafenib Preceded by Stereotactic Body Radiation Therapy for HCC
Administering stereotactic body radiation therapy (SBRT) prior to sorafenib significantly improves overall and ...
FEBRUARY 15, 2023
Tremelimumab/Durvalumab Combo Promising for Unresectable HCC
Combining a single priming dose of tremelimumab and durvalumab significantly improved overall survival in the ...
FEBRUARY 10, 2022
